Dicerna Pharmaceuticals, Inc. (DRNA) Social Stream
Dicerna Pharmaceuticals Inc (DRNA) Price Targets From Analysts
Use the tables below to see what analysts covering Dicerna Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
DRNA's average price target has moved up $3.5 over the prior 18 months.
Over the past 18 months, DRNA's average upside potential has been 33.86%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
DRNA Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 122 days, DRNA's average broker recommendation rating worsened by 1.08.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- Dicerna Pharmaceuticals Inc's upside potential (average analyst target price relative to current price) is greater than 26.41% of all US stocks.
- The variance in analysts' estimates of DRNA is less than -31.86% of Pharmaceutical Products stocks.
- The number of analysts covering the stock of DRNA is greater than 447.14% of Pharmaceutical Products stocks.
- DRNA has a higher average analyst price target than 238.61% of stocks in the mid market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Dicerna Pharmaceuticals Inc are GSK, FGEN and ARNA.
Is DRNA a Buy, Hold or Sell? See the POWR Ratings now!